Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) EBITDA: 2011-2024

Historic EBITDA for Tenax Therapeutics (TENX) over the last 11 years, with Dec 2024 value amounting to -$19.5 million.

  • Tenax Therapeutics' EBITDA rose 377.52% to $33.6 million in Q4 2016 from the same period last year, while for Dec 2016 it was $31.0 million, marking a year-over-year increase of 137.79%. This contributed to the annual value of -$19.5 million for FY2024, which is 352.82% down from last year.
  • As of FY2024, Tenax Therapeutics' EBITDA stood at -$19.5 million, which was down 352.82% from $7.7 million recorded in FY2023.
  • Tenax Therapeutics' EBITDA's 5-year high stood at $11.0 million during FY2022, with a 5-year trough of -$19.5 million in FY2024.
  • Over the past 3 years, Tenax Therapeutics' median EBITDA value was $7.7 million (recorded in 2023), while the average stood at -$245,144.
  • Per our database at Business Quant, Tenax Therapeutics' EBITDA grew by 17.36% in 2020 and then tumbled by 352.82% in 2024.
  • Yearly analysis of 4 years shows Tenax Therapeutics' EBITDA stood at $9.9 million in 2020, then reached $11.0 million in 2022, then slumped by 30.21% to $7.7 million in 2023, then tumbled by 352.82% to -$19.5 million in 2024.